BIOSTAR PHARM-B (02563) included in Hang Seng Composite Index constituents.

BIOSTAR PHARM-B (02563) announces that based on the index review results announced by Hang Seng Index Company Limited on February 21, 2025, the company has been selected by Hang Seng Index Company Limited and will be included as a constituent stock of the Hang Seng Composite Index. This change will be implemented after the market close on March 7, 2025, and will take effect from March 10, 2025. The board of directors believes that being included in the Hang Seng Composite Index reflects the market's high recognition of the company's business performance and value, and will help expand the shareholder base and increase the liquidity of its shares, thereby enhancing the company's investment value and reputation in the capital market.